ClinicalTrials.gg
Not yet recruitingNCT07943780uHRDNUpdated Nov 17, 2026

Combined Ultrasound Hepatic and Renal Denervation for Essential Hypertension

An interventional study of Ultrasound Denervation System in Essential Hypertension, sponsored by Shanghai Hantong Medical Technology Co., LTD. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Shanghai Hantong Medical Technology Co., LTD · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study will evaluate the safety and feasibility of a procedure that uses ultrasound energy to treat nerves around the arteries that supply the kidneys and liver. It will also assess whether blood pressure changes after the procedure in people whose high blood pressure remains inadequately controlled despite medication.

All participants who qualify will receive the study procedure. The study team will check for major safety events during the procedure and through 30 days afterward. The team will also compare the average systolic blood pressure measured over 24 hours before the procedure and at the 6-month follow-up.

The study will also look at changes in blood pressure medications and, for participants with type 2 diabetes, changes in blood sugar control.

Read the detailed description

This is a prospective, multicenter, open-label, single-arm exploratory study with a planned enrollment of 10 participants. The study includes participants with essential hypertension that remains inadequately controlled after at least 4 weeks of fixed-dose combination antihypertensive therapy. Participants may have hypertension with or without type 2 diabetes.

Before the procedure, computed tomography angiography or magnetic resonance angiography is used to assess vascular anatomy. Digital subtraction angiography is used during the procedure to confirm anatomical suitability. The investigational system consists of a single-use ultrasound ablation catheter and an ultrasound ablation generator. Treatment targets the main renal arteries and the main trunk of the common hepatic artery. First-order renal artery branches may also be treated if their anatomy meets the device requirements.

The study will summarize safety, blood pressure changes, and procedural feasibility descriptively. Measures of glucose metabolism will be explored in participants with type 2 diabetes.

02

Conditions studied

  • Essential Hypertension

Keywords

  • Ultrasound Denervation
  • Renal Denervation
  • Hepatic Denervation
  • Ambulatory Blood Pressure Monitoring
03

In context

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

This study's planned enrollment of 10 is below the median of 144 across 407 interventional studies indexed under Essential Hypertension.

Browse Essential Hypertension studies →

Lead sponsor

This is the only study on the registry with Shanghai Hantong Medical Technology Co., LTD as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 75 years, inclusive.
  2. Diagnosed with essential hypertension and inadequately controlled blood pressure, with or without type 2 diabetes mellitus (T2DM).
  3. After providing and after the investigator confirms that switching therapy is safe, participants must take study-supplied amlodipine 5 mg/day and irbesartan 150 mg/day. After at least 28 days of standardized therapy, office systolic blood pressure must be at least 150 mmHg and less than 180 mmHg, and mean 24-hour ambulatory systolic blood pressure must be at least 135 mmHg and less than 170 mmHg, as confirmed by ambulatory blood pressure monitoring.
  4. Participants with T2DM must meet all of the following:

    • of at least 24 kg/m².
    • of 7.0% to 9.0% at screening or within the preceding 3 months, and again on preprocedural retesting at Visit 3.
    • No changes in the types or doses of glucose-lowering medications for at least 4 weeks before Visit 3. In principle, the regimen should remain stable until completion of the 6-month primary endpoint assessment.

Exclusion criteria

Exclusion Criteria:

  1. Anatomy of either main renal artery or the main trunk of the common hepatic artery unsuitable for study treatment. Unsuitability of first-order renal artery branches for additional treatment is permitted.
  2. Any of the following on preprocedural computed tomography angiography, magnetic resonance angiography, or renal angiography:

    • Greater than 50% diameter stenosis in either main renal artery or the common hepatic artery.
    • Diameter less than 3 mm or greater than 8 mm in either main renal artery or the common hepatic artery.
  3. Previous renal artery denervation or hepatic artery denervation.
  4. History of (NYHA) class III or IV heart failure within 6 months before screening.
  5. Stroke or within 6 months before screening, or any prior stroke resulting in permanent disability.
  6. Type 1 diabetes mellitus, or insulin use within 6 months before screening in participants with T2DM.
  7. Secondary hypertension.
  8. Estimated below 40 mL/min/1.73 m², calculated using the 2021 CKD-EPI creatinine equation.
  9. Pregnancy, breastfeeding, or planned pregnancy during the study.
  10. Severe concomitant respiratory disease requiring long-term oxygen therapy or mechanical ventilation.
  11. History or evidence of active or suspected chronic liver or biliary tract disease.
  12. Current or previous chronic pancreatitis.
  13. Active severe infection, a marked bleeding tendency, or inability to receive perioperative anticoagulant or antiplatelet therapy.
  14. Any other condition that, in the investigator's judgment, precludes participation in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Combined Ultrasound Hepatic and Renal Denervation

    All enrolled participants receive combined ultrasound hepatic and renal denervation using the investigational ultrasound denervation system.

    Device: Ultrasound Denervation System

Interventions

  • DeviceUltrasound Denervation System

    The investigational system consists of a single-use ultrasound ablation catheter (model HR35-1050) and an ultrasound ablation generator (model U10-HR). The system delivers ultrasound energy for denervation along the main renal arteries and the main trunk of the common hepatic artery. First-order renal artery branches may also be treated if their anatomy meets the device requirements.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean 24-Hour Ambulatory Systolic Blood Pressure

    Change in mean 24-hour systolic blood pressure, measured by ambulatory blood pressure monitoring and reported in mmHg. Change is calculated as the 6-month value minus the baseline (Visit 2) value.

    Time frame: Baseline (Visit 2) and 6 months after the procedure

  2. Incidence of the composite endpoint of major safety events within 30 days after the procedure.

    Percentage of participants with at least one prespecified event: all-cause death, access-site complications requiring transfusion or invasive intervention or causing or prolonging hospitalization, target artery complications requiring intervention, new myocardial infarction, stroke, transient ischemic attack or other fatal, life-threatening or hospitalization-requiring cardiovascular or cerebrovascular events, acute kidney injury requiring dialysis or other serious renal events causing or prolonging hospitalization, acute liver failure or serious liver injury causing or prolonging hospitalization, acute pancreatitis, biliary tract or gallbladder complications requiring hospitalization or intervention, or other serious adverse events related to the device or procedure. Event relatedness to the device and to the procedure is assessed separately.

    Time frame: From vascular puncture at the start of the procedure through postprocedure Day 30, inclusive

Secondary outcomes

  1. Change From Baseline in Office Systolic Blood Pressure

    Change in office systolic blood pressure, reported in mmHg, calculated as the 6-month value minus the baseline (Visit 2) value.

    Time frame: Baseline (Visit 2) and 6 months after the procedure

  2. Change From Baseline in Office Diastolic Blood Pressure

    Change in office diastolic blood pressure, reported in mmHg, calculated as the 6-month value minus the Visit 2 value.

    Time frame: Baseline (Visit 2) and 6 months after the procedure

  3. Change From Baseline in Mean 24-Hour Ambulatory Diastolic Blood Pressure

    Change in mean 24-hour diastolic blood pressure measured by ambulatory blood pressure monitoring (ABPM), reported in mmHg.

    Time frame: Baseline (Visit 2) and 6 months after the procedure

  4. Change From Baseline in Mean Daytime Ambulatory Systolic Blood Pressure

    Change in mean daytime systolic blood pressure measured by ABPM, reported in mmHg.

    Time frame: Baseline (Visit 2) and 6 months after the procedure

  5. Change From Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure

    Change in mean daytime diastolic blood pressure measured by ABPM, reported in mmHg.

    Time frame: Baseline (Visit 2) and 6 months after the procedure

  6. Change From Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure

    Change in mean nighttime systolic blood pressure measured by ABPM, reported in mmHg.

    Time frame: Baseline (Visit 2) and 6 months after the procedure

  7. Change From Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure

    Change in mean nighttime diastolic blood pressure measured by ABPM, reported in mmHg.

    Time frame: Baseline (Visit 2) and 6 months after the procedure

  8. Proportion of Participants With Controlled Office Systolic Blood Pressure

    Percentage of participants with office systolic blood pressure below 140 mmHg at 6 months.

    Time frame: 6 months after the procedure

  9. Change From Baseline in the Composite Antihypertensive Medication Index

    Change in the protocol-defined composite antihypertensive medication index from Visit 2 to 6 months.

    Time frame: Baseline (Visit 2) and 6 months after the procedure

  10. Change From Baseline in Glycated Hemoglobin in Participants With Type 2 Diabetes

    Change in glycated hemoglobin (HbA1c), reported in percentage points, in participants with concomitant type 2 diabetes.

    Time frame: Baseline (Visit 3) and 6 months after the procedure

  11. Change From Baseline in Fasting Plasma Glucose in Participants With Type 2 Diabetes

    Change in fasting plasma glucose in participants with concomitant type 2 diabetes.

    Time frame: Baseline (Visit 3) and 6 months after the procedure

  12. Changes in Glucose-Lowering Medication Use in Participants With Type 2 Diabetes

    Changes in the types and doses of glucose-lowering medications in participants with concomitant type 2 diabetes.

    Time frame: Baseline (Visit 3) and 6 months after the procedure

  13. Device Success Rate

    Percentage of participants with successful device delivery, completion of planned energy delivery, and safe device withdrawal, without a device malfunction that prevents treatment completion.

    Time frame: During the procedure through device withdrawal

  14. Procedural Success Rate

    Percentage of participants in whom the intended ablation is completed at anatomically appropriate sites, including at least two sites in total across both kidneys and at least one site in the common hepatic artery, with the intended procedural objective achieved and no serious intraprocedural complications.

    Time frame: During the procedure through procedure completion

  15. Incidence of New Target Artery Stenosis or Vascular Lesions Requiring Intervention

    Percentage of participants with new diameter stenosis greater than 70% in a main renal artery, a treated first-order renal artery branch, or the main trunk of the common hepatic artery, or with a relevant vascular lesion requiring intervention. Assessed by computed tomography angiography, magnetic resonance angiography, or digital subtraction angiography if needed.

    Time frame: 6 months after the procedure

  16. Proportion of Participants With at Least a 30% Decline in Estimated Glomerular Filtration Rate

    Percentage of participants with a decline of at least 30% in estimated glomerular filtration rate from baseline. The first qualifying result is confirmed by repeat testing within 7 days, after excluding clearly reversible causes.

    Time frame: Baseline and 6 months after the procedure, with repeat testing within 7 days of a qualifying result

  17. Changes From Baseline in Hepatobiliary Laboratory Parameters

    Changes in alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transferase, total bilirubin, and direct bilirubin.

    Time frame: Baseline (Visit 3) and 6 months after the procedure

  18. Incidence of Hepatobiliary Complications

    Incidence of acute liver injury, biliary stricture or obstruction, acute cholecystitis, and other hepatobiliary complications requiring hospitalization or clinical intervention.

    Time frame: Assessed at 6 months after the procedure

  19. Changes From Baseline in Amylase and Lipase

    Changes in amylase and lipase from baseline to 6 months.

    Time frame: Baseline and 6 months after the procedure

  20. Incidence of Adverse Events Through 6 Months

    Percentage of participants with at least one adverse event.

    Time frame: From the start of the procedure through 6 months

  21. Incidence of Serious Adverse Events Through 6 Months

    Percentage of participants with at least one serious adverse event.

    Time frame: From the start of the procedure through 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — The sponsor does not plan to share individual participant data (IPD) from this study with other researchers.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

Of 80 interventional studies with no phase under Essential Hypertension, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 48. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Mar 30, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943780
Lead sponsor
Shanghai Hantong Medical Technology Co., LTD
Collaborators
Fudan University, Ruijin Hospital, Lanzhou University Second Hospital
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Dec 30, 2027 (estimated)
Completion
Mar 30, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

JinXin Tian
Contact
sunny.tian@han-med.com
8618817939689
Junbo Ge
principal investigator · hongshan Hospital, Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion